^
Association details:
Biomarker:THBS1 overexpression
Cancer:Ovarian Cancer
Regimen:CaT (carboplatin + paclitaxel)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy

Excerpt:
Microdissected formalin-fixed tumoral samples from 187 EOC patients’ primary tumors (90 and 97 samples from matched patients in the experimental and validation sets, respectively) were analyzed....Most of the patients (172 out of 187) received front-line carboplatin-paclitaxel regimen. Expression levels were correlated with overall (OS) and progression-free (PFS) survival by multivariate analysis. Patients with high TXN and THBS1 expression presented longer PFS (P=0.001 and P<0.001, respectively) and OS (P=0.024 and P<0.001, respectively).
DOI:
10.1038/tpj.2016.63